Interleukin 15 (IL15)-based near-infrared photoimmunotherapy
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04151-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Motofumi Suzuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892,…. Hauptthemen laut MEDLINE: Immunotherapy, Interleukin-15, Phototherapy, Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CCR NIH HHS, Center for Cancer Research, National Cancer Institute.
Abstract (Originalsprache)
Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective cancer therapy based on a targeted monoclonal antibody conjugated to phthalocyanine-based photoabsorber, IRDye700DX (IR700). Following injection, near-infrared light activates the conjugate causing direct cytotoxicity and immunogenic cell death. The high selectivity of NIR-PIT is traditionally based on the binding of a monoclonal antibody to its target thus bringing the photoabsorber, IR700, in close proximity to the cell membrane at the time of light exposure. However, other targeting moieties can be used and in the current study, interleukin-15 (IL15) is conjugated with IR700 to enable NIR-PIT. IL15-IR700 quickly bound to the cellular membrane of MC38 HIL15Rα cells that are transfected with human IL15 receptor alpha. NIR-PIT induced characteristic morphological changes accompanied by a significant decrease of cellular viability. Intratumoral injection of IL15-IR700 resulted in longer retention of the conjugate in the tumor compared to the intravenous injection. NIR-PIT with intratumoral IL15-IR700 significantly suppressed tumor growth, induced necrosis-like changes in tumor tissue, and stimulated host immune response. This study revealed that cytokine-based NIR-PIT is a potential therapeutic strategy for treating solid cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. kobayash@mail.nih.gov.
ORCID-Profile: Motofumi Suzuki, Aki Furusawa, Seiichiro Takao, Peter L Choyke, Hisataka Kobayashi
Förderung
- CCR NIH HHS
- Center for Cancer Research
- National Cancer Institute
Zitieren
APA
Suzuki, M., Furusawa, A., Yamamoto, H., Kano, M., Kano, M., Takao, S., Okuyama, S., Choyke, P. L., & Kobayashi, H. (2025). Interleukin 15 (IL15)-based near-infrared photoimmunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04151-8
Vancouver
Suzuki M, Furusawa A, Yamamoto H, Kano M, Kano M, Takao S, et al. Interleukin 15 (IL15)-based near-infrared photoimmunotherapy. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04151-8
BibTeX
@article{Suzuki2025,
author = {Suzuki, Motofumi and Furusawa, Aki and Yamamoto, Hiroshi and Kano, Makoto and Kano, Miyu and Takao, Seiichiro and Okuyama, Shuhei and Choyke, Peter L and Kobayashi, Hisataka},
title = {Interleukin 15 (IL15)-based near-infrared photoimmunotherapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04151-8}
}
EUVIMED